News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-02 EDT			5-day change	1st Jan Change
28.52 ^USD	+3.17%		+9.09%	-7.42%

07-03	Nordic stocks in North America, Ericsson fell 1.6%	FW
07-01	Nordic stocks in North America, AstraZeneca rose 1.3%	FW

All News

Mentions Relevance

06-30	Genmab hit a Phase 3 endpoint with epcoritamab in lymphoma	FW
06-29	Genmab Says Epcoritamab Combo Improves Progression-free Survival in Phase 3 Blood Cancer Study	MT
06-29	Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial	MT
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	BU
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	GL
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Demonstrating Statistically Significant Improvement in Progression-Free Survival	CI
06-24	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT
06-23	Genmab: Financing weighs now, pipeline pays later
06-17	Genmab A/S : has published its Articles of Association	PU
06-16	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
06-16	Capital Increase in Genmab as a Result of Employee Warrant Exercise	AQ
06-15	Major Shareholder Announcement	GL
06-15	Major Shareholder Announcement	AQ
06-15	Genmab A/S : has published its Articles of Association	PU
06-13	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	BU
06-13	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	GL
06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
06-11	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
06-11	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
05-29	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
05-21	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU